These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 15742456)

  • 21. Completion rate and compliance of anti-tuberculosis chemoprophylaxis in patients with rheumatic disease receiving tumor necrosis factor antagonists.
    Ideguchi H; Ohno S; Takase K; Kirino Y; Suda A; Ihata A; Ueda A; Takeno M; Nagaoka S; Ishigatsubo Y
    Clin Exp Rheumatol; 2010; 28(2):294-5. PubMed ID: 20483059
    [No Abstract]   [Full Text] [Related]  

  • 22. [Tolerance of anti-TNF alpha: the experience acquired in inflammatory rheumatic disease].
    Mariette X
    Ann Dermatol Venereol; 2006 May; 133(5 Pt 2):1S8-12. PubMed ID: 16967603
    [No Abstract]   [Full Text] [Related]  

  • 23. The 2005 International Symposium on Advances in Targeted Therapies: what have we learned in the 2000s and where are we going?
    Maini RN
    Ann Rheum Dis; 2005 Nov; 64 Suppl 4():iv106-8. PubMed ID: 16239377
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Non-TNF biologicals in therapy].
    Wollenhaupt J; Burmester GR
    Z Rheumatol; 2010 Sep; 69(7):579-80. PubMed ID: 20703491
    [No Abstract]   [Full Text] [Related]  

  • 25. Advances in targeted therapies XI.
    Breedveld FC; Kalden JR; Smolen JS
    Ann Rheum Dis; 2010 Jan; 69 Suppl 1():i1. PubMed ID: 19995739
    [No Abstract]   [Full Text] [Related]  

  • 26. Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005.
    Furst DE; Breedveld FC; Kalden JR; Smolen JS; Burmester GR; Bijlsma JW; Dougados M; Emery P; Keystone EC; Klareskog L; Mease PJ
    Ann Rheum Dis; 2005 Nov; 64 Suppl 4(Suppl 4):iv2-14. PubMed ID: 16239380
    [No Abstract]   [Full Text] [Related]  

  • 27. Updated consensus statement on biological agents, specifically tumour necrosis factor alpha (TNFalpha) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2004.
    Furst DE; Breedveld FC; Kalden JR; Smolen JS; Burmester GR; Bijlsma JW; Dougados M; Emery P; Keystone EC; Klareskog L; Mease PJ
    Ann Rheum Dis; 2004 Nov; 63 Suppl 2(Suppl 2):ii2-ii12. PubMed ID: 15479866
    [No Abstract]   [Full Text] [Related]  

  • 28. Advances in targeted therapies XIII.
    Breedveld FC; Kalden JR; Smolen JS
    Ann Rheum Dis; 2012 Apr; 71 Suppl 2():i1. PubMed ID: 22460135
    [No Abstract]   [Full Text] [Related]  

  • 29. Anti-tumour necrosis factor agents and lipid profile: a class effect?
    Garcês SP; Parreira Santos MJ; Vinagre FM; Roque RM; da Silva JA
    Ann Rheum Dis; 2008 Jun; 67(6):895-6. PubMed ID: 18474660
    [No Abstract]   [Full Text] [Related]  

  • 30. Anti-tumor necrosis factor therapies in immune-mediated rheumatic diseases. Other observations from the clinic.
    Russell AS; Rosenbaum JT
    J Rheumatol Suppl; 2010 May; 85():53-62. PubMed ID: 20436165
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Making tumor necrosis factor blockers safer: a prescriber's consumptive challenge.
    Keane J; Ní Cheallaigh C
    J Rheumatol; 2008 Jul; 35(7):1238-9. PubMed ID: 18597413
    [No Abstract]   [Full Text] [Related]  

  • 32. The application of infliximab (Remicade), a chimeric monoclonal antibody, in the treatment of rheumatic diseases.
    Kalden JR
    Isr Med Assoc J; 2000 Dec; 2 Suppl():11-2. PubMed ID: 11344856
    [No Abstract]   [Full Text] [Related]  

  • 33. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009.
    Furst DE; Keystone EC; Fleischmann R; Mease P; Breedveld FC; Smolen JS; Kalden JR; Braun J; Bresnihan B; Burmester GR; De Benedetti F; Dörner T; Emery P; Gibofsky A; Kavanaugh A; Kirkham B; Schiff MH; Sieper J; Singer N; Van Riel PL; Weinblatt ME; Weisman MH; Winthrop K
    Ann Rheum Dis; 2010 Jan; 69 Suppl 1():i2-29. PubMed ID: 19995740
    [No Abstract]   [Full Text] [Related]  

  • 34. Rheumatoid vasculitis treated with infliximab.
    van der Bijl AE; Allaart CF; Van Vugt J; Van Duinen S; Breedveld FC
    J Rheumatol; 2005 Aug; 32(8):1607-9. PubMed ID: 16078342
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Update in rheumatology: evidence published in 2011.
    Forbess LJ; Bass AR
    Ann Intern Med; 2012 Jul; 157(2):114-9. PubMed ID: 22801673
    [No Abstract]   [Full Text] [Related]  

  • 36. Drug insight: different mechanisms of action of tumor necrosis factor antagonists-passive-aggressive behavior?
    Rigby WF
    Nat Clin Pract Rheumatol; 2007 Apr; 3(4):227-33. PubMed ID: 17396108
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Emerging role of anti-tumor necrosis factor therapy in rheumatic diseases.
    Kalden JR
    Arthritis Res; 2002; 4 Suppl 2(Suppl 2):S34-40. PubMed ID: 12110156
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006.
    Furst DE; Breedveld FC; Kalden JR; Smolen JS; Burmester GR; Emery P; Keystone EC; Schiff MH; van Riel PL; Weinblatt ME; Weisman MH
    Ann Rheum Dis; 2006 Nov; 65 Suppl 3(Suppl 3):iii2-15. PubMed ID: 17038465
    [No Abstract]   [Full Text] [Related]  

  • 39. Patient-tailored therapy in rheumatoid arthritis: an editorial review.
    Scherer HU; Dörner T; Burmester GR
    Curr Opin Rheumatol; 2010 May; 22(3):237-45. PubMed ID: 20177384
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunology: Zoster vaccine and biologic agents: time to question a paradigm?
    Bongartz T; Orenstein R
    Nat Rev Rheumatol; 2012 Nov; 8(11):636-8. PubMed ID: 23027029
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.